



New valve features are designed for operational efficiency and optimized procedural performance



Maintains seal performance while positioning and locking the guidewire and pigtail catheter

THREADING PROVIDE FINER VALVE CONTROL



*Compared to our previous WATCHMAN Access Sheath.


DELIVERY CATHETER

Sheath Material

Braided Pebax® with PTFE liner and platinum/iridium marker band

WATCHMANTM LAAC DEVICE

Nitinol frame with Polyethylene Terephthalate (PET) fabric cover



ACCESS SYSTEM

Hub Material

Pebax® with polycarbonate

Sheath Material

Pebax® with PTFE liner and platinum/iridium marker band

Dilator


HDPE/LDPE high density polyethylene/Low density polyethylene (50:50 blend)


45 cm stiffer proximal shaft for enhanced kink resistance

75 cm working length

RADIOPAQUE MARKER BANDS

Helps guide precise sheath placement for the WATCHMAN device






SINGLE CURVE

ORDER NUMBER (GTIN)	REF/CATALOG NUMBER	ID	OD
08714729965701	M635TU70010	12F (4.2 mm)	14F (4.8 mm)






DOUBLE CURVE

ORDER NUMBER (GTIN)	REF/CATALOG NUMBER	ID	OD
08714729965718	M635TU70020	12F (4.2 mm)	14F (4.8 mm)





ANTERIOR CURVE

ORDER NUMBER (GTIN)	REF/CATALOG NUMBER	ID	OD
08714729965725	M635TU70040	12F (4.2 mm)	14F (4.8 mm)



BRIEF SUMMARY

WATCHMAN™ Left Atrial Appendage Closure Device with Delivery System and WATCHMAN Access System

INDICATIONS FOR USE

The WATCHMAN Device is indicated to reduce the risk of thromboembolism from the left atrial appendage in patients with non-valvular atrial fibrillation who:

- Are at increased risk for stroke and systemic embolism based on CHADS₂ or CHA,DS₂-VASc scores and are recommended for anticoagulation therapy;
- Are deemed by their physician to be suitable for warfarin; and
- Have an appropriate rationale to seek a non-pharmacologic alternative to warfarin, taking into account the safety and effectiveness of the device compared to warfarin.

The WATCHMAN Access System is intended to provide vascular and transseptal access for all WATCHMAN Left Atrial Appendage Closure Devices with Delivery Systems.

CONTRAINDICATIONS

Do not use the WATCHMAN Device if:

- Intracardiac thrombus is visualized by echocardiographic imaging.
- An atrial septal defect repair or closure device or a patent foramen ovale repair or closure device is present.
- The LAA anatomy will not accommodate a device. See Table 46 in the DFU.
- Any of the customary contraindications for other percutaneous catheterization procedures (e.g., patient size too small to accommodate TEE probe or required catheters) or conditions (e.g., active infection, bleeding disorder) are present.
- There are contraindications to the use of warfarin, aspirin, or clopidogrel.
- The patient has a known hypersensitivity to any portion of the device material or the individual components (see Device Description section) such that the use of the WATCHMAN Device is contraindicated.

WARNINGS

- Device selection should be based on accurate LAA measurements obtained using fluoro and ultrasound guidance (TEE recommended) in multiple angles (e.g., 0°, 45°, 90°, 135°).
- Do not release the WATCHMAN Device from the core wire if the device does not meet all release criteria.
- If thrombus is observed on the device, warfarin therapy is recommended until resolution of thrombus is demonstrated by TEE.
- The potential for device embolization exists with cardioversion <30 days following device implantation. Verify device position post-cardioversion during this period.
- Administer appropriate endocarditis prophylaxis for 6 months following device implantation. The decision to continue endocarditis prophylaxis beyond 6 months is at physician discretion.
- For single use only. Do not reuse, reprocess, or resterilize.

PRECAUTIONS

- The safety and effectiveness (and benefit-risk profile) of the WATCHMAN Device has not been established in patients for whom long-term anticoagulation is determined to be contraindicated.
- The LAA is a thin-walled structure. Use caution when accessing the LAA and deploying the device.
- Use caution when introducing the WATCHMAN Access System to prevent damage to cardiac structures.
- Use caution when introducing the Delivery System to prevent damage to cardiac structures.
- To prevent damage to the Delivery Catheter or device, do not allow the WATCHMAN
 Device to protrude beyond the distal tip of the Delivery Catheter when inserting
 the Delivery System into the Access Sheath.

- If using a power injector, the maximum pressure should not exceed 100 psi.
- In view of the concerns that were raised by the RE-ALIGN1 study of dabigatrain
 in the presence of prosthetic mechanical heart valves, caution should be used
 when prescribing oral anticoagulants other than warfarin in patients treated
 with the WATCHMAN Device. The WATCHMAN Device has only been evaluated
 with the use of warfarin post-device implantation.

ADVERSE EVENTS

Potential adverse events (in alphabetical order) which may be associated with the use of a left atrial appendage closure device or implantation procedure include but are not limited to:

Air embolism, Airway trauma, Allergic reaction to contrast media/medications or device materials, Altered mental status, Anemia requiring transfusion, Anesthesia risks, Angina, Anoxic encephalopathy, Arrhythmias, Atrial septal defect, AV fistula, Bruising, hematoma or seroma, Cardiac perforation, Chest pain/discomfort, Confusion post procedure, Congestive heart failure, Contrast related nephropathy, Cranial bleed, Decreased hemoglobin, Deep vein thrombosis, Death, Device embolism, Device fracture, Device thrombosis, Edema, Excessive bleeding, Fever, Groin pain, Groin puncture bleed, Hematuria, Hemoptysis, Hypotension, Hypoxia, Improper wound healing, Inability to reposition, recapture, or retrieve the device, Infection/ pneumonia, Interatrial septum thrombus, Intratracheal bleeding, Major bleeding requiring transfusion, Misplacement of the device/improper seal of the appendage/ movement of device from appendage wall, Myocardia erosion, Nausea, Oral bleeding, Pericardial effusion/tamponade, Pleural effusion, Prolonged bleeding from a laceration, Pseudoaneurysm, Pulmonary edema, Renal failure, Respiratory insufficiency/failure, Surgical removal of the device, Stroke - Ischemic, Stroke - Hemorrhagic, Systemic embolism, TEE complications (throat pain, bleeding, esophageal trauma), Thrombocytopenia, Thrombosis, Transient ischemic attack (TIA), Valvular damage, Vasovagal reactions.

There may be other potential adverse events that are unforeseen at this time.

CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician. Rx only. Prior to use, please see the complete "Directions for Use" for more information on Indications, Contraindications, Warnings, Precautions, Adverse Events, and Operator's Instructions.

©2015 Boston Scientific Corporation or its affiliates. All rights reserved.

1. Eikelboom JW, Connolly SJ, Brueckmann M, et al. N Engl J Med 2013;369:1206-14.



Interventional Cardiology 300 Boston Scientific Way Marlborough, MA 01752-1234 www.bostonscientific.com

To order product or for more information contact customer service at 1.888.272.1001

©2018 Boston Scientific Corporation or its affiliates. All rights reserved.

SH-581612-AA